[1]张 振,李 力,徐翠香,等.血清TAM和Cyfra21-1检测在食管癌诊断和化疗疗效判定中的价值[J].现代检验医学杂志,2015,30(04):150-152.[doi:10.3969/j.issn.1671-7414.2015.04.046]
　ZHANG Zhen,LI Li,X(¨overU)Cui-xiang,et al.Value of Detecting Serum TAM and Cyfra21-1 Levels in the Diagnosis and Chemotherapeutic Efficacy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):150-152.[doi:10.3969/j.issn.1671-7414.2015.04.046]
点击复制

血清TAM和Cyfra21-1检测在食管癌诊断和化疗疗效判定中的价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年04期
页码:
150-152
栏目:
检验与临床
出版日期:
2015-08-10

文章信息/Info

Title:
Value of Detecting Serum TAM and Cyfra21-1 Levels in the Diagnosis and Chemotherapeutic Efficacy of Esophageal Cancer
文章编号:
1671-7414(2015)04-150-03
作者:
张 振1; 李 力2; 徐翠香2; 李芒会2; 贺利民1; 马 磊1; 赵院利2
1.南阳市第一人民医院肿瘤科,河南南阳 473000;
2.陕西省人民医院,西安 710068
Author(s):
ZHANG Zhen1; LI Li2; X(¨overU)Cui-xiang2; LI Mang-hui2; HE Li-min1; MA Lei1; ZHAO Yuan-li2
1.Department of Oncology,the First People's Hospital of Nanyang City, Henan Nanyang 473000,China;
2.Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
食管癌;  肿瘤相关物质;  角化素蛋白片段19
分类号:
R735.1; R730.43
DOI:
10.3969/j.issn.1671-7414.2015.04.046
文献标志码:
A
摘要:
目的 探讨血清肿瘤相关物质(tumor associated material,TAM)和角化素蛋白片段19(Cyfra21-1)检测在食管癌诊断和化疗疗效判定中的价值。方法 选取2012年9月～2013年9月92例初诊食管癌和术后复发食管癌病人为研究对象,以同时期健康体检者为对照组,分别测定其血清TAM和Cyfra21-1水平,计算检测指标的灵敏度和特异度。另外,收集2012年9月～2014年4月化疗前血清TAM和Cyfra21-1均升高食管癌患者60例,化疗2周期后再次检测TAM和Cyfra21-1水平,以有效患者指标下降,进展患者指标上升计算判定符合率。结果 92例初诊和术后复发食管癌患者,血清TAM升高66例,Cyfra21-1升高47例,灵敏度分别为71.7%和51.1%(χ2=8.279,P=0.004)。对照组50例,TAM阴性47例,Cyfra21-1阴性46例,TAM特异度为94.0%,Cyfra21-1特异度为92.0%,差异无统计学意义(χ2=0.154,P=0.695)。接受化疗患者,有效25例,进展11例,TAM符合率为77.8%,Cyfra21-1符合率为75.0%,差异无统计学意义(χ2=0.077,P=0.781)。结论 TAM和Cyfra21-1为食管癌诊断和判定疗效的有用指标,并且TAM优于Cyfra21-1。
Abstract:
Objective To evaluate the levels of serum TAM and Cyfra21-1 in diagnosis and chemotherapeutic efficacy assessment of patientswith esophageal cancer.Methods The serum TAM and Cyfra21-1 levels were measured in 92 patients with initially diagnosed esophageal cancer or postoperative recurrence of esophageal cancer from September 2012 to September 2013 and 50 cases of healthy people in the same periods as control.The sensitivity and specificity of TAM and Cyfra21-1 were analyzed.Moreover,60 patients with high TAM and Cyfra21-1 levels before chemotherapy from September 2012to April 2014 were detected TAM and Cyfra21-1 levels after two cycles of chemotherapy.Relation between changes of TAM or Cyfra21-1 and chemotherapeutic efficacy were investigated.Results The diagnostic sensitivityof TAM for esophageal cancer was 71.7%,which was higher than that of Cyfra21-1(51.1%,P=0.004).The diagnostic specificity of TAM and Cyfra21-1 foresophageal cancer was 94.0% and 92.0% respectively.There were no significantly different between TAM and Cyfra21-1(P=0.695).Of patients undergoing chemotherapy,the overall response was 25 cases,progress was 11 cases.There wasno statistically significant difference in the coincidence rate of TAM and Cyfra21-1(77.8% vs 75.0%,P=0.781).Conclusion Detection of serum TAM and CYFRA21-1 was valuable in the diagnosis and assessment ofthe therapeutic efficacy of chemotherapy in patients with esophageal carcinoma.TAM was better than Cyfra21-1 in the diagnosis of esophageal carcinoma.

参考文献/References:

[1] 黄 镜,蔡锐刚,孟平均,等.紫杉醇联合顺铂治疗晚期食管鳞癌[J].中华肿瘤杂志,2004,26(12):753-755.
Huang J,Cai RG,Meng PJ,et al.PhaseⅡstudy of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus[J].Chinese Journal of Oncology,2004,26(12):753-755.
[2] Yamamoto K,Oka M,Hayashi H,et al.CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma[J].Cancer,1997,79(9):1647-1655.
[3] 张思维,张 敏,李光琳,等.2003～2007年中国食管癌发病与死亡分析[J].中国肿瘤,2012,21(4):241-247.
Zhang SW,Zhang M,Li GL,et al.An analysis of incidence and mortality of esophageal cancer in china,2003～2007[J].Bulletin of Chinese Cancer,2012,21(4):241-247.
[4] 王 涛,张 伟,刘 毅,等.血清细胞角蛋白19片段检测对食管癌的临床意义[J].中华医学杂志,2001,81(22):1390-1391.
Wang T,Zhang W,Liu Y,et al.Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer[J].National MedicalJournal of China,2001,81(22):1390-1391.
[5] Pujol JL,Grenier J,Daures JP,et al.Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer[J].Cancer Res,1993,53(1):61-66.
[6] Yi Y,Li BS,Sun HF,et al.Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma[J].Tumour Biol,2010,31(4):333-340.
[7] 顾金花,陈 玲,周丽娜,等.血清VEGF,SCC-Ag和CYFRA21-1对中晚期肺鳞癌化疗疗效评估的价值[J].现代检验医学杂志,2014,29(5):123-126.
Gu JH, Chen L, Zhou LN,et al.Value of serum VEGF,SCC-Ag and CYFRA21-1 for predicting response to chemotherapy in advanced lung squamous cellcarcinoma[J].Journal of Modern Laboratory Medicine,2014,29(5):123-126.
[8] Zhang HQ,Wang RB,Yan HJ,et al.Prognostic significance of CYFRA21-1,CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy[J].Asian Pac J Cancer Prev,2012,13(1):199-203.
[9] 陶 亚,廖经忠.血清PG和TAM联合检测对胃癌早期诊断的价值[J].中国现代医学杂志,2013,23(36):48-51.
Tao Y,Liao JZ.Clinical value of pepsinogen and se-rum tumor association material co-detection in the early diagnosis of gastric cancer[J].China Journal of Modern Medicine,2013,23(36):48-51.

相似文献/References:

[1]朱卫华,刘继斌.血浆相关基因甲基化在食管癌复发中的临床价值[J].现代检验医学杂志,2016,31(04):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
　ZHU Wei-hua,LIU Ji-bin.Clinical Significance of Promoter Hypermethylation of Esophageal Squamous Cell Carcinoma(ESCC)in Plasma[J].Journal of Modern Laboratory Medicine,2016,31(04):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
[2]肖小平,张 熊sub>a,秦光明b.食管癌和良性食管疾病患者血浆miRNA-21和miRNA-143检测的临床应用研究[J].现代检验医学杂志,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
　XIAO Xiao-ping,ZHANG Xionga,QIN Guang-mingb.Clinical Research of Detecting Plasma MiRNA-21 and MiRNA-143 for Identifying Early Esophageal Cancer and Benign Esophageal Diseases[J].Journal of Modern Laboratory Medicine,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
[3]邱 巍,胡 威,赵建江,等.江苏宿迁地区汉族人群DNMT3B基因启动子区-149C>T和-579G>T多态性与食管癌易感性的分析[J].现代检验医学杂志,2018,33(02):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　QIU Wei,HU Wei,ZHAO Jian-jiang,et al.Study on the Promoter Region -149C>T and -579G>T Polymorphism of DNMT3B with Genetic Susceptibility to Esophageal Cancer of Han Population in Jiangsu Suqian[J].Journal of Modern Laboratory Medicine,2018,33(04):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[4]陈　津,彭　伟,崔兆磊,等.食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估[J].现代检验医学杂志,2020,35(03):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
　CHEN Jin,PENG Wei,CUI Zhao-lei,et al.Serum KL-6 Predicts the Risk of Pneumonitis Induction after Radiotherapy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
[5]梁晓虎,郭俊霞,雷尚昆.食管癌组织中lnc RNA DNAJC3-AS1的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
　LIANG Xiao-hu,GUO Jun-xia,LEI Shangkun.Expression of Lnc RNA DNAJC3-AS1 in Esophageal Carcinoma Tissues and Its Correlation with Clinicopathological Features[J].Journal of Modern Laboratory Medicine,2021,36(04):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
[6]朱　娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
　ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(04):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[7]贾东辉,杜　宇,黄　飞,等.食管癌患者行根治性切除术后血清miR-216a和Bcl-2mRNA表达水平及与预后的相关性研究[J].现代检验医学杂志,2022,37(02):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
　JIA Dong-hui,DU Yu,HUANG Fei,et al.Expression Levels of Serum miR-216a and Bcl-2 mRNA and Their Correlation with Prognosis in Patients with Esophageal Cancer after Radical Resection[J].Journal of Modern Laboratory Medicine,2022,37(04):93.[doi:10.3969/j.issn.1671-7414.2022.02.020]
[8]刘 伟a,周 杨a,边 超a,等.miR-495 对食管癌细胞株Eca109 在不同放射剂量和顺铂浓度作用的影响及机制研究[J].现代检验医学杂志,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
　LIU Weia,ZHOU Yanga,BIAN Chaoa,et al.Effect of miR-495 on Esophageal Cancer Cell Line Eca109 at Different Radiation Doses and Cisplatin Concentrations and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
[9]周立远,叶玉祥,林 琳,等.LncRNA CCAT1 调节miR-155 表达增强CD8+T 细胞对食管癌抗肿瘤活性的机制研究[J].现代检验医学杂志,2023,38(03):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]
　ZHOU Li-yuan,YE Yu-xiang,LIN Lin,et al.Mechanism of LncRNA CCAT1 Regulating miR-155 Expression and Enhancing Anti-tumor Activity of CD8+T Cells Against Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2023,38(04):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]

备注/Memo

备注/Memo:
作者简介:张 振(1980-),男,硕士,主治医师,主要从事肿瘤临床及生物治疗研究工作,E-mail:zhzh77@163.com。
更新日期/Last Update: 2015-08-10